Drug Trial Radar · NCT06756126
A Clinical Study of AK120 in Adolescents With Moderate-to-severe Atopic Dermatitis (AD)
Last checked: Nov 19, 2026Latest source record: Jan 1, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
24
Planned (sponsor's estimate)
Start
Dec 30, 2024
Primary completion
Jun 30, 2025
Study completion Jun 30, 2025
Sponsor
- Lead sponsor
- AkesoIndustry
- Sponsor type
- Industry
- First posted
- Jan 1, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 12 years, up to 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a A multicenter, open label, phase II clinical study to evaluate the safety, pharmacokinetics (PK), pharmacodynamics(PD), and preliminary efficacy of AK120 in adolescents with moderate-to-severe atopic dermatitis
Conditions
- Atopic Dermatitis
Interventions
AK120Drug
AK120 subcutaneous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of adverse events(AE)Time frame: week -4 to week 16
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Dongguan People's Hospital
Dongguan, Guangdong, China
The Second Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China
The University of Hong Kong - Shenzhen Hospital
Shenzhen, Guangdong, China
Hunan Pediatric Medical Union
Changsha, Hunan, China
Xiangya Hospital Central South University
Changsha, Hunan, China
Ning Bo No.2 Hospital
Ningbo, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.